Solution
Faster R&D, with fewer samples.
Cut cohort costs, shorten go/no-go timelines, and surface multi-factor associations that single-variant methods miss.
The problem
Why this matters.
R&D teams across pharma, biotech, cosmetics, and agritech run studies that require large cohorts to reach statistical significance. This drives up costs, extends timelines, and delays critical go/no-go decisions.
Our approach
How we solve it.
EpiKern analyses the full informational content of your dataset — preserving individual-level precision that traditional methods discard. The result: statistically robust findings from dramatically fewer samples, without black-box models.
Expected gains
Tangible outcomes.
Fewer subjects, same analytical power.
From data collection to actionable insight.
Associations that single-variant methods miss.
Who uses this
Industries already applying it.
Let's discuss your challenge.
Tell us about your dataset, cohort size, or current bottleneck. We'll review and respond within a few working days.